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Dear Dr Zhou,
Boehringer Ingelheim, owner of the investigational drug linagliptin, would like to 
point out that in the recent review paper by Cox and colleagues,1 titled “Dipeptidyl 
peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and 
efficacy”, which was published in Drug, Healthcare and Patient Safety, the authors 
have   incorrectly described the mode of excretion for linagliptin as being predominantly 
renal. The correct statement should have read: “Excretion of linagliptin is predomi-
nantly nonrenal”, as described in the referenced pharmacokinetic study performed by 
Heise and colleagues.2 A nonrenal elimination route may be important in patients with 
renal impairment, which is common in patients with type 2 diabetes, so this distinction 
may be of clinical relevance. We would be grateful if you could clarify this for your 
readership to help avoid any confusion.
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